Literature DB >> 26985072

Management of stage IIIA (N2) non-small-cell lung cancer: a transatlantic perspective†.

Gaetano Rocco1, Katie Nason2, Alex Brunelli3, Gonzalo Varela4, Thomas Waddell5, David R Jones6.   

Abstract

Entities:  

Keywords:  N2 disease; Non-small-cell lung cancer; Staging; Treatment

Mesh：

Year:  2016        PMID： 26985072      PMCID： PMC4794446          DOI： 10.1093/ejcts/ezw040

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN： 1010-7940            Impact factor:   4.191


× No keyword cloud information.
  17 in total

1.  Invasive mediastinal staging is irrelevant for PET/CT positive N2 lung cancer if the primary tumour and ipsilateral lymph nodes are resectable.

Authors:  Eric Lim; Philip J McElnay; Gaetano Rocco; Alessandro Brunelli; Gilbert Massard; Alper Toker; Bernward Passlick; Gonzalo Varela; Walter Weder
Journal:  Lancet Respir Med       Date:  2015-09       Impact factor: 30.700

2.  The significance of one-station N2 disease in the prognosis of patients with nonsmall-cell lung cancer.

Authors:  Panagiotis Misthos; Evangelos Sepsas; John Kokotsakis; Ion Skottis; Achilleas Lioulias
Journal:  Ann Thorac Surg       Date:  2008-11       Impact factor: 4.330

Review 3.  Outcome of surgery versus radiotherapy after induction treatment in patients with N2 disease: systematic review and meta-analysis of randomised trials.

Authors:  P J McElnay; A Choong; E Jordan; F Song; E Lim
Journal:  Thorax       Date:  2015-05-12       Impact factor: 9.139

4.  The Society of Thoracic Surgeons and the European Society of Thoracic Surgeons general thoracic surgery databases: joint standardization of variable definitions and terminology.

Authors:  Felix G Fernandez; Pierre E Falcoz; Benjamin D Kozower; Michele Salati; Cameron D Wright; Alessandro Brunelli
Journal:  Ann Thorac Surg       Date:  2015-01       Impact factor: 4.330

5.  Which subgroup of patients with pathologic N2 non-small cell lung cancer benefit from surgery?

Authors:  Yasunobu Funakoshi; Yukiyasu Takeuchi; Hidenori Kusumoto; Toru Kimura; Hajime Maeda
Journal:  J Cancer Res Clin Oncol       Date:  2012-02-25       Impact factor: 4.553

6.  Management of stage IIIA non-small cell lung cancer by thoracic surgeons in North America.

Authors:  Nirmal K Veeramachaneni; Richard H Feins; Briana J K Stephenson; Lloyd J Edwards; Felix G Fernandez
Journal:  Ann Thorac Surg       Date:  2012-06-27       Impact factor: 4.330

7.  Now or later: evaluating the importance of chemotherapy timing in resectable stage III (N2) lung cancer in the National Cancer Database.

Authors:  Daniel J Boffa; Jacquelyn G Hancock; Xiaopan Yao; Sarah Goldberg; Joshua E Rosen; Anthony W Kim; Amy Moreno; Frank C Detterbeck
Journal:  Ann Thorac Surg       Date:  2014-11-20       Impact factor: 4.330

8.  Survival of patients with unsuspected pN2 non-small cell lung cancer after an accurate preoperative mediastinal staging.

Authors:  Carme Obiols; Sergi Call; Ramon Rami-Porta; Juan Carlos Trujillo-Reyes; Roser Saumench; Manuela Iglesias; Mireia Serra-Mitjans; Guadalupe Gonzalez-Pont; Jose Belda-Sanchís
Journal:  Ann Thorac Surg       Date:  2013-11-26       Impact factor: 4.330

9.  Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Gerard A Silvestri; Anne V Gonzalez; Michael A Jantz; Mitchell L Margolis; Michael K Gould; Lynn T Tanoue; Loren J Harris; Frank C Detterbeck
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

Review 10.  The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement.

Authors:  Renato G Martins; Thomas A D'Amico; Billy W Loo; Mary Pinder-Schenck; Hossein Borghaei; Jamie E Chaft; Apar Kishor P Ganti; Feng-Ming Spring Kong; Mark G Kris; Inga T Lennes; Douglas E Wood
Journal:  J Natl Compr Canc Netw       Date:  2012-05       Impact factor: 11.908
View more
  3 in total

1.  New P16 Expression Criteria Predict Lymph Node Metastasis in Patients With Non-small Cell Lung Cancer.

Authors:  Hyo Jung An; Hyun Min Koh; Dae Hyun Song
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

2.  Long-term clinical outcomes and prognostic factors of upfront surgery as a first-line therapy in biopsy-proven clinical N2 non-small cell lung cancer.

Authors:  Luca Bertolaccini; Elena Prisciandaro; Juliana Guarize; Lara Girelli; Giulia Sedda; Niccolò Filippi; Filippo de Marinis; Lorenzo Spaggiari
Journal:  Front Oncol       Date:  2022-07-28       Impact factor: 5.738

Review 3.  Role of endobronchial ultrasound-guided transbronchial needle aspiration in staging of lung cancer: a thoracic surgeon's perspective.

Authors:  Giulio Melloni; Federico Mazza; Massimiliano Venturino; Davide Turello
Journal:  Mediastinum       Date:  2021-03-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.